Overall transparency scores for companies with novel drugs or biologics FDA approved in 2016 or 2017
| Rank | Company | Company size | Patient trials score, % (proportion) | FDAAA score, % (proportion) | Data sharing score, % | Overall score, % |
| 1 | AbbVie | Large | 100 (10/10) | 100 (10/10) | 100 | 100 |
| 1 | Amgen | Large | 100 (16/16) | 100 (15/15) | 100 | 100 |
| 1 | Bayer | Large | 100 (5/5) | 100 (4/4) | 100 | 100 |
| 1 | Merck KGaA/EMD Serono | Large | NA | NA | 100 | 100 |
| 1 | Novartis | Large | 100 (7/7) | 100 (3/3) | 100 | 100 |
| 1 | Roche/Genentech | Large | 100 (11/11) | 100 (9/9) | 100 | 100 |
| 1 | Takeda | Non-large | 100 (2/2) | 100 (2/2) | 100 | 100 |
| 8 | Merck Sharp & Dohme | Large | 94 (32/34) | 100 (27/27) | 98 | 97 |
| 9 | Novo Nordisk | Large | 100 (15/15) | 89 (8/9) | 100 | 96 |
| 9 | Sanofi | Large | 93 (37/40) | 95 (21/22) | 99 | 96 |
| 11 | Shire | Large | 100 (8/8) | 86 (6/7) | 100 | 95 |
| 12 | Biogen | Large | 100 (9/9) | 100 (4/4) | 80 | 93 |
| 12 | Johnson & Johnson/Janssen | Large | 100 (8/8) | 80 (4/5) | 100 | 93 |
| 14 | Eli Lilly | Large | 93 (14/15) | 100 (11/11) | 80 | 91 |
| 15 | Gilead | Large | 89 (17/19) | 94 (16/17) | 80 | 88 |
| 16 | Ultragenyx | Non-large | 100 (2/2) | 100 (2/2) | 60 | 87 |
| 17 | AstraZeneca | Large | 83 (10/12) | 70 (7/10) | 100 | 84 |
| 17 | Pfizer | Large | 88 (7/8) | 86 (6/7) | 78 | 84 |
| 19 | Celgene | Large | NA | NA | 80 | 80 |
| 20 | Radius | Non-large | 100 (4/4) | 50 (2/4) | 80 | 77 |
| 21 | Ferrer | Non-large | 100 (3/3) | 100 (2/2) | 20 | 73 |
| 21 | Portola | Non-large | 100 (4/4) | 100 (2/2) | 20 | 73 |
| 21 | Puma Biotechnology | Non-large | 100 (6/6) | 100 (5/5) | 20 | 73 |
| 24 | Teva | Non-large | 100 (2/2) | 50 (1/2) | 60 | 70 |
| 25 | Lexicon | Non-large | 100 (4/4) | 75 (3/4) | 20 | 65 |
| 25 | Shionogi | Non-large | 100 (7/7) | 80 (4/5) | 14 | 65 |
| 27 | Neurocrine Biosciences | Non-large | 100 (6/6) | 80 (4/5) | 20 | 62 |
| 27 | Valeant | Non-large | 67 (2/3) | 100 (1/1) | 20 | 62 |
| 29 | Aerie | Non-large | 100 (7/7) | 57 (4/7) | 20 | 59 |
| 29 | La Jolla | Non-large | 67 (2/3) | 100 (1/1) | 10 | 59 |
| 31 | US Worldmeds | Non-large | 50 (7/14) | 100 (3/3) | 16 | 55 |
| 32 | Regeneron | Non-large | 80 (8/10) | 0 (0/8) | 80 | 53 |
| 33 | Bausch Health/Bausch and Lomb | Non-large | 71 (5/7) | 0 (0/6) | 80 | 50 |
| 34 | Melinta Therapeutics | Non-large | 100 (4/4) | 25 (1/4) | 20 | 48 |
| 34 | Mitsubishi Tanabe | Non-large | 80 (4/5) | NA | 16 | 48 |
| 36 | Chemo Research | Non-large | 75 (3/4) | NA | 7 | 41 |
| 37 | Lupin | Non-large | 100 (3/3) | 0 (0/3) | 20 | 40 |
| 37 | The Medicines Company/Rempex | Non-large | 50 (1/2) | 50 (1/2) | 20 | 40 |
| 37 | Tesaro | Non-large | 100 (2/2) | 0 (0/1) | 20 | 40 |
| 40 | BioMarin | Non-large | 0 (0/1) | 0 (0/1) | 40 | 13 |
| 40 | Synergy | Non-large | 20 (1/5) | 0 (0/5) | 20 | 13 |
| 42 | PTC Therapeutics | Non-large | 25 (1/4) | 0 (0/2) | 8 | 11 |
| Median (IQR) | 100 (80–100) | 88 (50–100) | 69 (20–100) | 73 (54–95) | ||
| Percentage of companies fully meeting measure | 58 (23/40) | 42 (16/38) | 26 (11/42) | 17 (7/42) | ||
Data sharing scores are after 30-day amendment window (see online supplemental table 1 for pre-amendment scores). Takeda acquired Shire in 2019. Shionogi enacted a new data sharing policy in 2018; the company score reflects the company policy at time of drug approval in 2017. Novartis acquired The Medicines Company in 2020. Valeant became Bausch Health in 2018. Bausch Health acquired Synergy’s assets in 2019. These acquisitions happened after our study cutoff date. At the time of drug approval, Tesaro did not have a publicly available data sharing policy, which is reflected in its score. Tesaro has since been acquired by GlaxoSmithKline.
FDAAA, Food and Drug Administration Amendments Act.